1. Home
  2. SFBS vs ACAD Comparison

SFBS vs ACAD Comparison

Compare SFBS & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ServisFirst Bancshares Inc.

SFBS

ServisFirst Bancshares Inc.

HOLD

Current Price

$76.89

Market Cap

4.0B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$26.19

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFBS
ACAD
Founded
2005
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.4B
IPO Year
2014
2004

Fundamental Metrics

Financial Performance
Metric
SFBS
ACAD
Price
$76.89
$26.19
Analyst Decision
Buy
Buy
Analyst Count
2
22
Target Price
$80.00
$30.00
AVG Volume (30 Days)
271.6K
1.2M
Earning Date
01-20-2026
02-25-2026
Dividend Yield
1.94%
N/A
EPS Growth
24.86
98.53
EPS
4.67
1.54
Revenue
$497,701,000.00
$1,047,118,000.00
Revenue This Year
$24.89
$15.16
Revenue Next Year
$17.02
$11.79
P/E Ratio
$16.76
$16.86
Revenue Growth
16.24
12.69
52 Week Low
$66.48
$13.40
52 Week High
$93.90
$28.35

Technical Indicators

Market Signals
Indicator
SFBS
ACAD
Relative Strength Index (RSI) 56.16 47.74
Support Level $74.25 $25.90
Resistance Level $80.00 $27.06
Average True Range (ATR) 1.96 0.76
MACD 0.33 -0.20
Stochastic Oscillator 60.47 39.36

Price Performance

Historical Comparison
SFBS
ACAD

About SFBS ServisFirst Bancshares Inc.

Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary, ServisFirst Bank. Through the bank, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: